Metabolomics in oncology

Cancer Rep (Hoboken). 2023 Mar;6(3):e1795. doi: 10.1002/cnr2.1795. Epub 2023 Feb 21.

Abstract

Background: Oncogenic transformation alters intracellular metabolism and contributes to the growth of malignant cells. Metabolomics, or the study of small molecules, can reveal insight about cancer progression that other biomarker studies cannot. Number of metabolites involved in this process have been in spotlight for cancer detection, monitoring, and therapy.

Recent findings: In this review, the "Metabolomics" is defined in terms of current technology having both clinical and translational applications. Researchers have shown metabolomics can be used to discern metabolic indicators non-invasively using different analytical methods like positron emission tomography, magnetic resonance spectroscopic imaging etc. Metabolomic profiling is a powerful and technically feasible way to track changes in tumor metabolism and gauge treatment response across time. Recent studies have shown metabolomics can also predict individual metabolic changes in response to cancer treatment, measure medication efficacy, and monitor drug resistance. Its significance in cancer development and treatment is summarized in this review.

Conclusion: Although in infancy, metabolomics can be used to identify treatment options and/or predict responsiveness to cancer treatments. Technical challenges like database management, cost and methodical knowhow still persist. Overcoming these challenges in near further can help in designing new treatment régimes with increased sensitivity and specificity.

Keywords: biomarker; cancer; metabolic reprogramming; metabolism; metabolomics.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Magnetic Resonance Imaging
  • Medical Oncology
  • Metabolomics* / methods
  • Neoplasms* / diagnosis
  • Neoplasms* / metabolism
  • Neoplasms* / therapy

Substances

  • Biomarkers